Payment overview · 2025
General Payments
$42.27
2 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel J Monahan, MD
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1548209141
Verified facts
What the public records show
CMS Open Payments records show Daniel J Monahan, MD received $42.27 in general payments during 2025 across 2 reported records.
Smith+Nephew, Inc. accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $24.41 | 57.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.86 | 42.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $42.27 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 804 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 781 | 217 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 116 |
| Lisinopril | Lisinopril | 321 | 88 |
| Eliquis | Apixaban | 277 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 45 |
| Alprazolam | Alprazolam | 265 | 63 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 243 | 77 |
| Gabapentin | Gabapentin | 236 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 63 |
| Metformin Hcl | Metformin Hcl | 208 | 61 |
| Simvastatin | Simvastatin | 198 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 56 |
| Meloxicam | Meloxicam | 176 | 61 |
| Omeprazole | Omeprazole | 172 | 52 |
| Tramadol Hcl | Tramadol Hcl | 172 | 50 |
| Furosemide | Furosemide | 164 | 49 |
| Jardiance | Empagliflozin | 149 | 28 |
| Prednisone | Prednisone | 148 | 86 |
| Donepezil Hcl | Donepezil Hcl | 146 | 43 |
| Azithromycin | Azithromycin | 142 | 114 |
| Alendronate Sodium | Alendronate Sodium | 141 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 62 |
| Oxycodone Hcl | Oxycodone Hcl | 137 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 43 |
| Ozempic | Semaglutide | 131 | 17 |
| Potassium Chloride | Potassium Chloride | 124 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 21 |
| Sertraline Hcl | Sertraline Hcl | 118 | 36 |
| Mounjaro | Tirzepatide | 113 | 21 |
| Famotidine | Famotidine | 112 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 70 |
| Allopurinol | Allopurinol | 106 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 38 |
| Trazodone Hcl | Trazodone Hcl | 102 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 98 | 29 |
| Atenolol | Atenolol | 96 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 14 |
| Glimepiride | Glimepiride | 89 | 28 |
| Carvedilol | Carvedilol | 85 | 22 |
| Clonazepam | Clonazepam | 83 | 24 |
| Lorazepam | Lorazepam | 81 | 39 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 80 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 18 |
| Azelastine Hcl | Azelastine Hcl | 68 | 29 |
| Morphine Sulfate Er | Morphine Sulfate | 68 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 13 |
| Xarelto | Rivaroxaban | 63 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 19 |
| Warfarin Sodium | Warfarin Sodium | 60 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 47 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 42 |
| Valacyclovir | Valacyclovir Hcl | 52 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 13 |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Topiramate | Topiramate | 48 | 12 |
| Bupropion Hcl | Bupropion Hcl | 47 | 14 |
| Nifedipine Er | Nifedipine | 44 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 19 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Valsartan | Valsartan | 39 | 13 |
| Amoxicillin | Amoxicillin | 38 | 27 |
| Montelukast Sodium | Montelukast Sodium | 37 | 14 |
| Methadone Hcl | Methadone Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 15 |
| Cephalexin | Cephalexin | 33 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 12 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fentanyl | Fentanyl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Aricept | Donepezil Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $42.27 · 2 records | Smith+Nephew, Inc. | CREON, LINZESS, PICO 7 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error